Please assess the completion status of the following clinical trial:

Trial Title: Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Planned anesthesia with use of LMA (laryngeal mask airway)~* Planned duration of anesthesia between 0.5 and 2 hours~* Age between 18-75 years~* Both gender~* Body mass index (BMI) \<35~* ASA 1-3~* Written informed consent prior to study participation~Exclusion Criteria:~* Planned additional regional and local anesthesia~* Contra-indication for the use of a laryngeal mask airway~* Asthma~* COPD IV~* Known allergy or hypersensitivity to any drugs administered during this study~* Women who are pregnant, breast-feeding or women of childbearing potential not using adequate contraceptive methods~* Participation in a drug or device trial within the previous 30 days.~* Patients legally unable to give written informed consent.~* Patients with severe psychiatric disorders~* Recent (\<6 months) history of alcohol or drug abuse~* Patients with severe neuropsychiatric disorders~* Non-fluency in German language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- desflurane (Type: EXPERIMENTAL): Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
- sevoflurane (Type: ACTIVE_COMPARATOR): Sevoflurane:~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application
- propofol (Type: ACTIVE_COMPARATOR): Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application

Based on this trial design, predict the completion outcome and termination type (if applicable).